Joshua LaBaer, director of the Virginia G. Piper Center for Personalized Diagnostics and chair of the Biodesign Institute directorate at Arizona State University, has been named president of the US Human Proteome Organization.
NHLBI in late January put out an RFP for the program, which calls for researchers to develop proteomics technologies and apply them to solve clinical puzzles. It is set to begin early next year, shortly after its current two major proteomics initiatives expire.
The panel of proteomics experts told attendees of the annual meeting of the US Human Proteome Organization that the science is not ready for clinical use and the discipline has become marginalized compared to genomics.
Some researchers, like Ruedi Aebersold, claim that because tools such as mass specs are in a "perpetual discovery mode, the high-performance application of the [the tools] will remain in specialized labs."